Percutaneous NephrolithotomyNCT05947435
Tranexamic Acid in Percutaneous Nephrolithotomy
A study testing Tranexamic acid in people with Percutaneous Nephrolithotomy and Intraoperative Use of Tranexamic Acid, run by Haseki Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Tranexamic acid, once a randomly used antifibrinolytic agent, has been in standard protocols for many specific surgeries. Studies are still needed to standardize the dose and route of tranexamic acid administration, examine its possible contributions in urological surgery, and establish a protocol for its use. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Percutaneous Nephrolithotomy, Intraoperative Use of Tranexamic Acid
- What is being tested?
- Tranexamic acid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 75 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2022to 1 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18-70 years old
- ASA I-III patients
- scheduled for PCNL surgery
Who cannot join
- tranexamic acid hypersensitivity
- history of subarachnoid haemorrhage
- previous cerebrovascular event
- a history of arterial-venous embolism or a tendency to thromboembolism
- abnormal liver function tests
- unstable cardiovascular disease
- acute or chronic renal failure
- the presence of any haematological disease and known colour blindness
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Haseki Training and Research Hospital
Istanbul, Sultangazi, 34000
About this study
Official title: The Effect of Use of Tranexamic Acid in Percutaneous Nephrolithotomy on Blood Loss and Surgical Visual Clarity
Tranexamic acid, once a randomly used antifibrinolytic agent, has been in standard protocols for many specific surgeries. Studies are still needed to standardize the dose and route of tranexamic acid administration, examine its possible contributions in urological surgery, and establish a protocol for its use.
To contribute to this goal, the study was designed as a prospective, randomized, double-blind study on 75 patients with one control and 2 study groups (n=25) who underwent percutaneous nephrolithotomy. Group Tranexamic acid received 10 mg/kg intravenous tranexamic acid preoperatively. And Group Irrigation received the same amount in the initial irrigation fluid. Primarily,the total amount of blood transfusion and the changes in haemoglobin and haematocrit values during two postoperative days were observed. Distinctively, continuous intraoperative haemoglobin saturation was monitored. Secondarily, surgical visual clarity with a standard visual score was questioned to reveal its contribution to surgical practicality, operative time, and residual fragment quantity.
Read the detailed description
The study was designed as a double-blind, prospective, randomised, controlled study after approval of our Institutional ethics committee (dossier no: 108-2021) and assessed patients scheduled for PCNL after January 2022 for eligibility. After obtaining written informed consent, 75 patients (3 groups; 1:1:1 distribution; n=25) were allocated, and the study was conducted in Haseki Training and Research Hospital until May 2023, with the principles outlined in the Helsinki Declaration.
Study subjects The study population was 18-70 years old and ASA I-III patients scheduled for PCNL surgery. Exclusion criteria were tranexamic acid hypersensitivity, history of subarachnoid haemorrhage, previous cerebrovascular event, a history of arterial-venous embolism or a tendency to thromboembolism, abnormal liver function tests, unstable cardiovascular disease, acute or chronic renal failure, presence of any haematological disease and known colour blindness.
Patient randomization and blindness Randomization was designed as 3 (n= 25) named Groups A, B, and Group C in a 1:1:1 ratio with a computer-based algorithm and sealed in opaque envelopes by the surgeon assigned to the study. The investigative anesthesiologist selected an envelope in the order of numbers on it, and Group A continued with an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision. In Group B, 10 mg/kg tranexamic acid was placed in the first irrigation solution; in Group C, no drug was given either way. The urologist was blind to the study groups and was the evaluator of an intraoperative visual score. Postoperative Hb and Hct values and complications were followed by the surgeons who were also blinded to the groups, and the decision of blood replacement was made according to the Hct values according to our standard protocol of the urology department.
Anaesthesia and surgical technique All surgeries were performed under general anaesthesia with standard monitorisation and non-invasive MASIMO Hemoglobin (SpHb®) real-time monitoring. After the ureteral catheter was placed, the patient was placed in a prone position. After sequential dilatations were performed under fluoroscopy, a 16.5 Fr or 21 Fr am Platz sheath was placed in the pelvicalyceal system. Ho: YAG Laser lithotripter (Sphinx, Lisa laser, USA) was used to fragment stones. According to the surgeon's decision, a JJ stent and/or a nephrostomy tube were placed at the final of the operation.
Primary outcome The primary outcome was the comparison of changes in haemoglobin and haematocrit values during two postoperative days with changes in intraoperative SpHb values and postoperative need for blood transfusion. SpHb was monitored throughout the surgery; however, the value of change before and immediately after surgery was a major concern. Blood samples were evaluated for Hb and Hct values on the first night and the second morning after surgery. Indications for blood transfusion were below 30% hematocrit level.
Secondary outcomes The effect on surgical outcomes was questioned by residual fragment (%) and postoperative complications. The effect on surgical practice was evaluated by operation time (minute) and visual score of the surgeon. At the end of the surgery, the assigned surgeon who was blind to the groups was asked to rate the visual clarity by a score pre-designed for arthroscopic surgeries as 'Bad-Medium, Good or Perfect'. A visual scoring from 1 to 10 was used, with 10 for the perfect image, 4-10 as good and 1-4 as bad-medium. We searched for bleeding, angioembolisation, infection, reoperation, and thrombotic complications, especially pulmonary emboli.
Statistical analysis and sample size calculation The mean sample size was calculated using the G Power 3.1 analysis program. The sample size was estimated at 90% power and 8% significance level, and it was determined that at least 20 patients per group were required to obtain a statistically significant value. Therefore, we included 25 patients in each group to prevent possible dropouts.
The Statistical Package for the Social Sciences version 27 (SPSS IBM Corp., Armonk, NY, USA) program was used. The normality of the distribution of the variables was checked by the Shapiro-Wilk test and Q-Q plots. The one-way ANOVA test or Kruskal-Wallis test was used for the comparison of continuous variables. Comparison between groups was performed with Tukey posthoc analysis. Qualitative data are shown as mean ± standard deviation or median (IQR). Quantitative data are shown as mean ± standard deviation values. The data were analyzed at a 95% confidence level.
- Being tested
- Tranexamic acid
- Keywords
- blood loss, percutaneous nephrolithotomy, tranexamic acid, visual image quality
- Medical subject headings
- Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tranexamic acidDrug
Also called Transamin®
Tranexamic acid was administered in intravenous or locally within irrigation fluid
| Study group | Role | What they receive |
|---|---|---|
| Tranexamic acid IV | Experimental | Group A received an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision. Receives: Drug: Tranexamic acid |
| Tranexamic acid irrigation | Experimental | 10 mg/kg tranexamic acid was placed in the first irrigation solution Receives: Drug: Tranexamic acid |
| Control | No intervention | The control group did not receive tranexamic acid in either way |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hemoglobin decrease
Hemoglobin decrease after postoperative first and second day relevant to preoperative values
Measured: postoperative 48 hours
Blood product requirement
number of packed red blood cell use
Measured: postoperative 48 hours
Secondary outcomes (1)
surgical visual score
A visual scoring from 1 to 10 was used, with 10 for the perfect image, 4-10 as good and 1-4 as bad-medium
Measured: intraoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2023
- Study start1 Jan 2022
- Primary completion1 May 2023
- Study completion1 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Percutaneous NephrolithotomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 75 participants (actual)
Sponsor and investigators
- Lead sponsor
- Haseki Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Berna Caliskan, Haseki Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05947435
- Sponsor's protocol ID
- 108-2021
- Status last verified
- Jul 2023
- First submitted
- 7 Jul 2023
- Last updated
- 19 Jul 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Ersin M, Demirel M, Buget MI, Edipoglu IS, Atalar AC, Ersen A. The effect of intravenous tranexamic acid on visual clarity during arthroscopic rotator cuff repair: A randomized, double-blinded, placebo-controlled pilot study. Acta Orthop Traumatol Turc. 2020 Nov;54(6):572-576. doi: 10.5152/j.aott.2020.19164.
PubMed 33423986Kim J, Alrumaih A, Donnelly C, Uy M, Hoogenes J, Matsumoto ED. The impact of tranexamic acid on perioperative outcomes in urological surgeries A systematic review and meta-analysis. Can Urol Assoc J. 2023 Jun;17(6):205-216. doi: 10.5489/cuaj.8254.
PubMed 36952300
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Use of Tranexamic Acid in Percutaneous Nephrolithotomy on Blood Loss and Surgical Visual Clarity
- ClinicalTrials.gov ID
- NCT05947435
- Acronym / sponsor ID
- 108-2021
- Keywords
- blood loss, percutaneous nephrolithotomy, tranexamic acid, visual image quality
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 75 participants (actual)
- Lead sponsor
- Haseki Training and Research HospitalUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 1 May 2023 (actual)
- Study completion
- 1 Jun 2023 (actual)
- First posted
- 17 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tranexamic acid, once a randomly used antifibrinolytic agent, has been in standard protocols for many specific surgeries. Studies are still needed to standardize the dose and route of tranexamic acid administration, examine its possible contributions in urological surgery, and establish a protocol for its use.
To contribute to this goal, the study was designed as a prospective, randomized, double-blind study on 75 patients with one control and 2 study groups (n=25) who underwent percutaneous nephrolithotomy. Group Tranexamic acid received 10 mg/kg intravenous tranexamic acid preoperatively. And Group Irrigation received the same amount in the initial irrigation fluid. Primarily,the total amount of blood transfusion and the changes in haemoglobin and haematocrit values during two postoperative days were observed. Distinctively, continuous intraoperative haemoglobin saturation was monitored. Secondarily, surgical visual clarity with a standard visual score was questioned to reveal its contribution to surgical practicality, operative time, and residual fragment quantity.
Detailed description
The study was designed as a double-blind, prospective, randomised, controlled study after approval of our Institutional ethics committee (dossier no: 108-2021) and assessed patients scheduled for PCNL after January 2022 for eligibility. After obtaining written informed consent, 75 patients (3 groups; 1:1:1 distribution; n=25) were allocated, and the study was conducted in Haseki Training and Research Hospital until May 2023, with the principles outlined in the Helsinki Declaration.
Study subjects The study population was 18-70 years old and ASA I-III patients scheduled for PCNL surgery. Exclusion criteria were tranexamic acid hypersensitivity, history of subarachnoid haemorrhage, previous cerebrovascular event, a history of arterial-venous embolism or a tendency to thromboembolism, abnormal liver function tests, unstable cardiovascular disease, acute or chronic renal failure, presence of any haematological disease and known colour blindness.
Patient randomization and blindness Randomization was designed as 3 (n= 25) named Groups A, B, and Group C in a 1:1:1 ratio with a computer-based algorithm and sealed in opaque envelopes by the surgeon assigned to the study. The investigative anesthesiologist selected an envelope in the order of numbers on it, and Group A continued with an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision. In Group B, 10 mg/kg tranexamic acid was placed in the first irrigation solution; in Group C, no drug was given either way. The urologist was blind to the study groups and was the evaluator of an intraoperative visual score. Postoperative Hb and Hct values and complications were followed by the surgeons who were also blinded to the groups, and the decision of blood replacement was made according to the Hct values according to our standard protocol of the urology department.
Anaesthesia and surgical technique All surgeries were performed under general anaesthesia with standard monitorisation and non-invasive MASIMO Hemoglobin (SpHb®) real-time monitoring. After the ureteral catheter was placed, the patient was placed in a prone position. After sequential dilatations were performed under fluoroscopy, a 16.5 Fr or 21 Fr am Platz sheath was placed in the pelvicalyceal system. Ho: YAG Laser lithotripter (Sphinx, Lisa laser, USA) was used to fragment stones. According to the surgeon's decision, a JJ stent and/or a nephrostomy tube were placed at the final of the operation.
Primary outcome The primary outcome was the comparison of changes in haemoglobin and haematocrit values during two postoperative days with changes in intraoperative SpHb values and postoperative need for blood transfusion. SpHb was monitored throughout the surgery; however, the value of change before and immediately after surgery was a major concern. Blood samples were evaluated for Hb and Hct values on the first night and the second morning after surgery. Indications for blood transfusion were below 30% hematocrit level.
Secondary outcomes The effect on surgical outcomes was questioned by residual fragment (%) and postoperative complications. The effect on surgical practice was evaluated by operation time (minute) and visual score of the surgeon. At the end of the surgery, the assigned surgeon who was blind to the groups was asked to rate the visual clarity by a score pre-designed for arthroscopic surgeries as 'Bad-Medium, Good or Perfect'. A visual scoring from 1 to 10 was used, with 10 for the perfect image, 4-10 as good and 1-4 as bad-medium. We searched for bleeding, angioembolisation, infection, reoperation, and thrombotic complications, especially pulmonary emboli.
Statistical analysis and sample size calculation The mean sample size was calculated using the G Power 3.1 analysis program. The sample size was estimated at 90% power and 8% significance level, and it was determined that at least 20 patients per group were required to obtain a statistically significant value. Therefore, we included 25 patients in each group to prevent possible dropouts.
The Statistical Package for the Social Sciences version 27 (SPSS IBM Corp., Armonk, NY, USA) program was used. The normality of the distribution of the variables was checked by the Shapiro-Wilk test and Q-Q plots. The one-way ANOVA test or Kruskal-Wallis test was used for the comparison of continuous variables. Comparison between groups was performed with Tukey posthoc analysis. Qualitative data are shown as mean ± standard deviation or median (IQR). Quantitative data are shown as mean ± standard deviation values. The data were analyzed at a 95% confidence level.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Tranexamic acid IV | Experimental | Drug: Tranexamic acidGroup A received an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision. |
| Tranexamic acid irrigation | Experimental | Drug: Tranexamic acid10 mg/kg tranexamic acid was placed in the first irrigation solution |
| Control | No intervention | –The control group did not receive tranexamic acid in either way |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 18-70 years old
- ASA I-III patients
- scheduled for PCNL surgery
Key exclusion criteria (8 listed)
- tranexamic acid hypersensitivity
- history of subarachnoid haemorrhage
- previous cerebrovascular event
- a history of arterial-venous embolism or a tendency to thromboembolism
- abnormal liver function tests
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tranexamic acidAlso: Transamin®Tranexamic acid was administered in intravenous or locally within irrigation fluid | Drug | Tranexamic acid IV, Tranexamic acid irrigation |
Primary outcome
Hemoglobin decrease
Time frame: postoperative 48 hours
Hemoglobin decrease after postoperative first and second day relevant to preoperative values
Blood product requirement
Time frame: postoperative 48 hours
number of packed red blood cell use
1 secondary outcome
surgical visual score
Time frame: intraoperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2023.
- Background: PubMed 33423986Ersin M, Demirel M, Buget MI, Edipoglu IS, Atalar AC, Ersen A. The effect of intravenous tranexamic acid on visual clarity during arthroscopic rotator cuff repair: A randomized, double-blinded, placebo-controlled pilot study. Acta Orthop Traumatol Turc. 2020 Nov;54(6):572-576. doi: 10.5152/j.aott.2020.19164.
- Results publication: PubMed 36952300Kim J, Alrumaih A, Donnelly C, Uy M, Hoogenes J, Matsumoto ED. The impact of tranexamic acid on perioperative outcomes in urological surgeries A systematic review and meta-analysis. Can Urol Assoc J. 2023 Jun;17(6):205-216. doi: 10.5489/cuaj.8254.
- Individual participant dataSharing planned: Undecided
Related trials for Percutaneous Nephrolithotomy
Recruiting
Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis
Kidney Stone
Recruiting
Supine vs. Prone Mini-PCNL in Children
Kidney Calculi (or Renal Calculi / Nephrolithiasis), Supine Mini Percutaneous Nephrolithotomy
Recruiting
Nephrostomy Tract Infiltration for Pain Control After PCNL
Postoperative Pain, Kidney Calculi
Recruiting
Safety and Efficacy of Papillary Versus NonPapillary Access During Percutaneous Nephrolithotomy
Safety, Efficacy
Not yet recruitingPhase 4
Effect of a Low-Dose Ketamine-Dexmedetomidine-Based Opioid-Sparing Anesthesia Protocol on Postoperative Quality of Recovery After Percutaneous Nephrolithotomy
Nephrolithiasis, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tranexamic acid in people with Percutaneous Nephrolithotomy and Intraoperative Use of Tranexamic Acid, run by Haseki Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hemoglobin decrease (time frame: postoperative 48 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05947435, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2023.